NCT06673693View on ClinicalTrials.gov

Tislelizumab Combined With SBRT for the Treatment of Head and Neck Squamous Cell Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 15, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2029

Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC)HNSCC
Interventions
DRUG

Tislelizumab

SBRT

Trial Locations (2)

510060

NOT_YET_RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER